MedPath

Ventricular Pace Suppression Study

Not Applicable
Completed
Conditions
Pacemaker Indication
Interventions
Device: VpS algorithm in EVIA and ENTOVIS pacemakers
Registration Number
NCT01053832
Lead Sponsor
Biotronik SE & Co. KG
Brief Summary

Investigation of the efficacy and safety of the Ventricular Pace Suppression (VpS) algorithm.

Detailed Description

The aim of this study is to investigate the percentage of reduction of ventricular pacing using the VpS feature of the EVIA/ENTOVIS pacemaker in a controlled clinical investigation.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
84
Inclusion Criteria
  • Paroxysmal AV block and/or Sinus Node Dysfunction
  • DDD(R)-ADI(R)-Mode (VpS Algorithm) applicability
Exclusion Criteria
  • Permanent AV block III°
  • Permanent Atrial Fibrillation/ Flutter
  • Require mode other than DDD(R)-ADI(R) or DDD(R)
  • Have a life expectancy of less than six months
  • Expected to receive heart surgery within six months
  • Enrolled in another cardiac investigation

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Ventricular Pace Suppression- ONVpS algorithm in EVIA and ENTOVIS pacemakers-
Ventricular Pace Suppression- OFFVpS algorithm in EVIA and ENTOVIS pacemakers-
Primary Outcome Measures
NameTimeMethod
Reduction of right ventricular pacing with the help of the VpS algorithm in the EVIA/ ENTOVIS pacemakers.6-8 months
Secondary Outcome Measures
NameTimeMethod
A Complication free rate >95%, with respect to the VpS feature of the implanted pacemaker.6-8 months

Trial Locations

Locations (2)

Klinikum Coburg gGmbH

🇩🇪

Coburg, Bavaria, Germany

Abteilung für Elektrophysiologie, Klinik für Kardiologie und Angiologie, UNIVERSITÄTSKLINIKUM Schleswig-Holstein

🇩🇪

Kiel, Schleswig-Holstein, Germany

© Copyright 2025. All Rights Reserved by MedPath